

# *In Vitro* Antifungal Activity of Novel Triazole EFINACONAZOLE and Five Comparators against Dermatophyte Isolates

Ali Rezaei-Matehkolaei,<sup>a</sup> Sadegh Khodavaisy,<sup>b</sup> Mohamad Mahdi Alshahni,<sup>c,d</sup> Takashi Tamura,<sup>c,d</sup> Kazuo Satoh,<sup>c,d</sup> Mahdi Abastabar,<sup>e</sup> Gholam Reza Shokoohi,<sup>f</sup> Bahram Ahmadi,<sup>g</sup> Mohammad kord,<sup>b</sup> Simin Taghipour,<sup>a</sup> Koichi Makimura,<sup>c,d</sup> Hamid Badali<sup>e,h</sup>

**ABSTRACT** The objective of this study was to assess the *in vitro* activity of the novel triazole antifungal drug, efinaconazole, and five comparators (luliconazole, lanconazole, terbinafine, itraconazole, and fluconazole) against a large collection of *Trichophyton interdigitale* and *Trichophyton rubrum* clinical isolates. The geometric mean MICs were the lowest for luliconazole (0.0005  $\mu$ g/ml), followed by lanconazole (0.002  $\mu$ g/ml), efinaconazole (0.007  $\mu$ g/ml), terbinafine (0.011  $\mu$ g/ml), itraconazole (0.095  $\mu$ g/ml), and fluconazole (12.77  $\mu$ g/ml). It appears that efinaconazole, lanconazole, and luliconazole are promising candidates for the treatment of dermatophytosis due to *T. interdigitale* and *T. rubrum*.

**KEYWORDS** dermatophytes, efinaconazole, *in vitro* susceptibility testing